research Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
This study reports that a patient with subacute cutaneous lupus erythematosus experienced disease exacerbation after the first dose of the BNT162b2 mRNA COVID-19 vaccine, but tolerated the second dose without adverse reactions.
